We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Irbesartan: a review of its use in hypertension and diabetic nephropathy.
- Authors
Croom KF; Plosker GL
- Abstract
Irbesartan (APROVEL, AVAPRO, IRBETAN, KARVEA), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension. It is also approved in some regions for the treatment of nephropathy in patients with hypertension and type 2 diabetes mellitus. In adults with essential hypertension, irbesartan is effective at reducing blood pressure (BP) over a 24-hour period with once-daily administration. Irbesartan also slows the progression of renal disease in hypertensive patients with type 2 diabetes, with this effect partly independent of its BP-lowering effect. In addition, irbesartan was generally well tolerated in clinical trials. Thus, irbesartan is a useful treatment option for patients with hypertension, including those with type 2 diabetes and nephropathy.
- Publication
Drugs, 2008, Vol 68, Issue 11, p1543
- ISSN
0012-6667
- Publication type
Journal Article
- DOI
10.2165/00003495-200868110-00008